Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs.

Fang J, Jensen ES, Boudreaux MK, Du LM, Hawkins TB, Koukouritaki SB, Cornetta K, Wilcox DA.

Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9583-8. doi: 10.1073/pnas.1016394108. Epub 2011 May 23.

2.

New Insights Into the Treatment of Glanzmann Thrombasthenia.

Poon MC, Di Minno G, d'Oiron R, Zotz R.

Transfus Med Rev. 2016 Apr;30(2):92-9. doi: 10.1016/j.tmrv.2016.01.001. Epub 2016 Jan 30. Review.

3.

Glanzmann thrombasthenia: state of the art and future directions.

Nurden AT, Pillois X, Wilcox DA.

Semin Thromb Hemost. 2013 Sep;39(6):642-55. doi: 10.1055/s-0033-1353393. Epub 2013 Aug 8. Review.

4.

Clinical, biochemical, and molecular aspects of Glanzmann's thrombasthenia in humans and dogs.

Boudreaux MK, Lipscomb DL.

Vet Pathol. 2001 May;38(3):249-60. Review.

PMID:
11355654
5.

Glanzmann's thrombasthenia: updated.

Nair S, Ghosh K, Kulkarni B, Shetty S, Mohanty D.

Platelets. 2002 Nov;13(7):387-93. Review.

PMID:
12487785
6.

Glanzmann thrombasthenia-like syndromes associated with Macrothrombocytopenias and mutations in the genes encoding the αIIbβ3 integrin.

Nurden AT, Pillois X, Fiore M, Heilig R, Nurden P.

Semin Thromb Hemost. 2011 Sep;37(6):698-706. doi: 10.1055/s-0031-1291380. Epub 2011 Nov 18. Review.

PMID:
22102273
7.

Disorders of platelet function.

Bennett JS, Kolodziej MA.

Dis Mon. 1992 Aug;38(8):577-631. Review.

PMID:
1321709
8.

Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues.

Di Minno G, Coppola A, Di Minno MN, Poon MC.

Thromb Haemost. 2009 Dec;102(6):1157-64. doi: 10.1160/TH09-04-0225. Review.

PMID:
19967146
9.

Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia.

Wilcox DA, White GC 2nd.

J Thromb Haemost. 2003 Nov;1(11):2300-11. Review.

10.

Congenital disorders associated with platelet dysfunctions.

Nurden P, Nurden AT.

Thromb Haemost. 2008 Feb;99(2):253-63. doi: 10.1160/TH07-09-0568. Review.

PMID:
18278172
11.

Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment.

Nurden AT, Pillois X, Nurden P.

Expert Rev Hematol. 2012 Oct;5(5):487-503. doi: 10.1586/ehm.12.46. Review.

PMID:
23146053
12.

[Glanzmann's thrombasthenia: a rare example of an integrin deficit].

Perutelli P, Mori PG.

Recenti Prog Med. 1992 Oct;83(10):577-81. Review. Italian.

PMID:
1462042
13.

The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.

Coller BS, Shattil SJ.

Blood. 2008 Oct 15;112(8):3011-25. doi: 10.1182/blood-2008-06-077891. Review.

14.

Platelet glycoprotein IIb/IIIa receptors and Glanzmann's thrombasthenia.

French DL, Seligsohn U.

Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):607-10. Review. No abstract available.

15.

Glanzmann thrombasthenia.

Nurden AT.

Orphanet J Rare Dis. 2006 Apr 6;1:10. Review.

16.

Inherited platelet disorders.

Sandrock-Lang K, Wentzell R, Santoso S, Zieger B.

Hamostaseologie. 2016 Aug 3;36(3):178-86. doi: 10.5482/HAMO-14-11-0067. Epub 2015 Feb 24. Review.

PMID:
25707719
17.

Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses?

Nurden AT.

Blood Rev. 2017 Apr 4. pii: S0268-960X(17)30007-3. doi: 10.1016/j.blre.2017.03.005. [Epub ahead of print] Review.

PMID:
28395882

Supplemental Content

Support Center